Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAD and DAD-IO Trial: SG + EV +/- Pembrolizumab in mUC
NCT04724018Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2021
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in urothelial carcinoma (UC), sponsored by Dana-Farber Cancer Institute. Started May 2021; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04724018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724018.